Hungarian biotechnology and AI company Turbine Network Analysis Research Development Ltd. has been awarded HUF 250 million of EU and government funding to create a virtual lab, the company told MTI.
The digital lab is a software platform used to create and run simulated experimental protocols and analyse large amounts of biological data.
Founded in 2015, Turbine is a Hungarian biotechnology and artificial intelligence (AI) company that develops data-driven solutions in the fields of drug discovery and cancer therapies. The company’s goal is to accelerate drug development by simulating and analyzing cellular-level processes. Their proprietary AI-based cell simulation platform models biological networks and signal transduction processes.
To date, the company has collaborated with researchers from leading biotechnology and pharmaceutical companies such as MSD, AstraZeneca, and Bayer, as well as Japan’s ONO Pharma, which specializes in cancer research.
The company currently employs more than 80 people, but aims to expand its team to over 100 by the end of 2026, with an increasing proportion of international experts. The company had HUF 2.2bn net revenue in 2024, public records show.
Top 5 Articles
Duna House Profit Climbs Nearly 70% in Q3 November 24, 2025 
What Awaits the Hungarian Economy in 2026 and 2027? April 24, 2026 
'Recharge' Campaign Launched to Boost Domestic Tourism January 21, 2026 
Hungary’s Growth Stalls as Inflation Returns to Target Range February 6, 2026 
Business, Consumer Confidence at Two-Year High in April April 23, 2026
